Silymarin 420mg 24 Months Meta-Analysis: Cirrhosis Mortality -30%, Child-Pugh -28% Across 18 RCTs
WELLNESS

Silymarin 420mg 24 Months Meta-Analysis: Cirrhosis Mortality -30%, Child-Pugh -28% Across 18 RCTs

By Sophie · · Hepatology 2026
KO | EN

Silymarin (milk thistle standardized extract) 420mg/day for 24 months across 18 RCTs (2,460 cirrhosis patients with hepatitis B/C, alcoholic, NAFLD progression) reduced all-cause mortality by 30%, Child-Pugh score by 28%, ALT by 38%, AST by 32%, GGT by 42%, albumin +18%, ascites by 25%, variceal bleeding by 22%, hepatic encephalopathy by 28% (Hepatology 2026 meta-analysis). Standard matrix validation for the era of chronic hepatitis B/C, alcoholic, and NAFLD progression in Korea.

The meta-analysis synthesized PubMed, EMBASE, Cochrane RCTs from 2010-2025 in 18 trials with 2,460 cirrhosis patients (Child-Pugh A, B, C). Silymarin 420mg/day (silybin/silydianin/silychristin standardized, Legalon or Silybin Phytosome) for 24 months. Results: all-cause mortality -30% (95% CI -42 to -18), Child-Pugh -28%, MELD -22%, ALT -38%, AST -32%, GGT -42%, albumin +18%, bilirubin -25%, ascites -25%, variceal bleeding -22%, hepatic encephalopathy -28%. Side effects: minimal (GI 5%).

Silymarin — RCT Validation of 2,000-Year Herb

What it is:

  • Silybum marianum (milk thistle, Western thistle)
  • Seed extract core: silybin (silibinin) 50% + silydianin + silychristin
  • 2,000+ year medicinal use in Greece and Rome
  • German BfArM 1986 liver protection registered (Legalon, prescription drug)
  • Silybin Phytosome (Indena) absorption +5x

Mechanisms:

  • Direct antioxidant (glutathione +35%)
  • Hepatocyte membrane stabilization → toxin penetration block
  • Collagen synthesis ↓ → fibrosis progression -25%
  • Hepatocyte regeneration stimulation (differentiation + proliferation)
  • Cytokines (TNF-α, IL-6) -32%
  • Toxin protection (alcohol, acetaminophen, aflatoxin)

Cirrhosis — 10,000+ New Diagnoses Annually in Korea

Korean statistics:

  • Hepatitis B carriers 3-4% (1.8 million)
  • Hepatitis C carriers 0.6% (300,000)
  • Alcoholic liver disease 30%+ (NIAAA criterion drinkers)
  • NAFLD 30%+ (especially obesity, diabetes)
  • 10,000+ new cirrhosis diagnoses annually
  • 5-year survival Child-Pugh A 90%, B 70%, C 30%

Progression stages:

  • F0-F2: reversible, recoverable with matrix
  • F3 (advanced fibrosis): partial reversal possible (some NAFLD)
  • F4 (cirrhosis): partial reversal possible (when cause blocked)
  • Decompensated cirrhosis: irreversible, transplant evaluation

420mg/day — 24-Month Critical Dose

Dose matrix:

  • 100-200mg/day: general support (prevention, mild ALT ↑)
  • 420mg/day: cirrhosis, chronic hepatitis (current meta-analysis standard)
  • 600-800mg/day: progressive hepatitis (some RCTs)
  • 24+ months cumulative evaluation

Selection criteria:

  • Legalon (Madaus, prescription drug) — Korean insurance covered
  • Silybin Phytosome (Indena Siliphos) — absorption +5x
  • General standardized extract (silybin 30%+) 30,000-80,000 KRW per 60 capsules
  • Non-standardized extracts have variable efficacy

Matrix — NAC, TUDCA, Choline, Curcumin Synergy

Cirrhosis matrix:

  • Silymarin 420mg/day (antioxidant, fibrosis block)
  • NAC 1,200mg/day (glutathione synthesis)
  • TUDCA 500-1,000mg/day (bile acid, ER stress)
  • Choline/phosphatidylcholine 1,500mg/day (lipid metabolism)
  • Curcumin + piperine 1g/day (inflammation, fibrosis)
  • Physician collaboration + standard treatment (essential)

Cautions

Drug interactions:

  • Anticoagulants (warfarin, DOAC): physician evaluation
  • CYP3A4, UGT drugs (mesothelin, sirolimus) effects
  • Anticancer drugs: physician evaluation (cisplatin, methotrexate synergy)
  • Pregnancy/lactation: physician decision (insufficient safety evidence)

Side effects:

  • GI discomfort under 5%
  • Allergy (Asteraceae family allergy check)
  • 24+ months cumulative evaluation, partial at 6 months

Cirrhosis Integrated Treatment Matrix

Tier 1 cause block: Hepatitis B/C drugs (entecavir, DAA), alcohol cessation, weight ↓ (NAFLD) Tier 2 natural matrix: Silymarin + NAC + TUDCA + choline + curcumin 24 months Tier 3 complications: Ascites, varices, hepatic encephalopathy management Tier 4 transplant evaluation: Child-Pugh C, MELD 15+ for transplant assessment Tier 5 tracking: ALT/AST/albumin/bilirubin every 6 months, liver ultrasound/abdominal CT annually

Korean Market — Silymarin Standardized Extract

Distribution:

  • Legalon (Madaus, prescription): insurance covered, physician prescription
  • Silybin Phytosome direct purchase: 80,000-150,000 KRW
  • General supplement: 30,000-80,000 KRW per 60 capsules
  • Physician collaboration recommended (cirrhosis diagnosed)

Global Silymarin Market

Germany: BfArM 1986 liver protection registered, pharmaceutical standard Europe: WHO monograph registered US: NIH NAFLD/HCV/cirrhosis 30+ RCTs cumulative Korea: Prescription pharmaceutical + supplement market growing

Spring 2026, silymarin 420mg/day for 24 months meta-analysis across 18 RCTs (2,460 patients) validating cirrhosis mortality -30%, Child-Pugh -28%, ALT -38% marks not just an herb but a multi-target matrix for liver function recovery + fibrosis block + mortality block. With NAC, TUDCA, choline, curcumin — Spring 2026 liver·detox matrix.